Management of Massive Necrotizing Fasciitis Excision

Download Case Study PDF

Patient History

A 39-year-old male presented with aggressive necrotizing fasciitis in the torso and extremities. The origin of the infected tissue was unclear. Infected and necrotic tissues were debrided across the entire torso, right axilla, right upper arm and forearm, bilateral flanks, bilateral groins, bilateral anterior thighs, scrotum, and base of the penis. The total excised area was 4,832 cm² with exposed fascia, muscle, and several ribs.

Treatment

Following debridement, large applications of Restrata Meshed were applied to the wound and secured with staples. Abdominal pads were also used. A second application of Restrata Meshed was applied 19 days after the initial application. Viable granulation tissue was observed starting 21 days after the initial application of Restrata. Day 35, healthy granulation tissue sufficiently covered the left torso and bilateral thighs. The patient was taken to the OR for the first of many split-thickness skin graft (STSG) procedures in order to achieve full wound closure. This process of STSG was repeated for various parts including, the back, right torso, right upper thigh, right arm, right axilla, and genitalia.

Conclusion

Day 63, the patient was noted to be awake, alert, and capable of walking with assistance. Grafted regions estimated to have 95% graft take with minor graft loss due to location and body position. Most recently, 123 days after initial Restrata application, only minor openings remain with all other regions fully integrated.

Patient Presents Post Excision

Day 0

Initial application of Restrata Meshed

Day 7

1 week post application

Day 16

Granulation tissue present

Day 19

2nd application of Restrata Meshed on abdomen

Day 24

5 days after 2nd application

Day 35

Before STSG and After STSG

Day 35

Right arm developing healthy granulation bed

Day 38

Day 50

10 days after 2nd application of Restrata Meshed on right arm

Day 52

Day 59

5 days post STSG on right arm

Day 73

Day 123

Only minor openings remain with all other regions fully integrated

*Infection was controlld and no longer present at the time of the inital Restrata application.

**Disclaimer: Restrata has not been studied in wounds that extend into the tendon, muscle, joint capsule, or bone. Restrata should not be applied until excessive exudate, bleeding, acute swelling, and infection is controlled. Please refer to the Instructions for Use for a full list of indications, contraindications, precautions, and warnings.

MKG-30164

Related Clinical Case Studies

Necrotizing Fasciitis of Chest and Neck

Patient presented with necrotizing fasciitis after injecting a mixture of meth and industrial cleaner into her neck, missing the vein. Using Restrata, the wound was taken to eventual closure via secondary intent. Three months after the initial application, the patient was discharged.

Traumatic Gunshot Wound

After 3 applications, Restrata helped to provide a better-granulated tissue base for a STSG in this complex wound.

Contact an account executive today!

Get Started

or call (844) 879-2237

Revolutionizing Healing. Changing Lives.

•

Cerafix®, Covora®, and Restrata® are registered trademarks of Acera Surgical Inc.

•

Privacy & Security

This website, Acera-Surgical.com, is owned and operated by Acera Surgical. We are strongly committed to protecting the privacy of our website users. The intent of our privacy policy is to inform you, the user, about the information that we may collect about visitors to our site, how we use that information, and about our disclosure practices.

Acera Surgical is committed to high standards that require honesty, integrity and fairness. Acera Surgical will collect no personal information about you unless you choose to provide that information to us. We do not use techniques that collect personal information about you without your knowledge. You have the right to decline to have any information collected or transferred for marketing purposes.

What Happens To Your Personal Information?

All personal information that is collected on our website is stored in a secure location. At no time will Acera Surgical solicit personal information to third party vendors without prior consent, as we respect the privacy and confidentiality of our website visitors.

What About Spam?

Subscribers will not receive any unsolicited emails or correspondence if they have not provided Acera Surgical with prior permission. From time to time, we may use email as a way to keep in touch with our website visitors; however, we do not send “spam” (unsolicited marketing email). If you agree to receive email communications from us, every email message we send to you will include an email address to which you can respond. If at any time you decide you do not want to receive marketing email from us, simply let us know and we will remove your name and email address from our mailing list.

When You Leave This Site

This policy discloses the privacy practices for our website. However, our site contains links to other sites. Once you link to another site, you are subject to the privacy and security policies of the new site. We encourage you to read the privacy policies of all websites you visit, especially if you share any personal information.

Security Policy

Users are prohibited from violating or attempting to violate the security of the site. By way of example, you are prohibited from (a) accessing data not intended for such user or logging onto a server or an account which the user is not authorized to access; (b) attempting to probe, scan or test the vulnerability of a system or network or to breach security without proper authorization; (c) attempting to interfere with service to any user, host or network; (d) sending unsolicited mail, including promotions and/or advertising of products or services.